Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies

References

• Reichert JM. Antibodies to watch in 2014: Mid-year update. mAbs 2014; 6:799-802; PMID:24846335; http://dx.doi.org/10.4161/mabs.29282
   PubMed Web of Science ®Google Scholar
• Huang X, Wang S, Lee C-K, Yang X, Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett 2011; 307:72-9; PMID:21497990; http://dx.doi.org/10.1016/j.canlet.2011.03.019
   PubMed Web of Science ®Google Scholar
• Gayle SS, Castellino RC, Buss MC, Nahta R. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. Curr Med Chem 2013; 20:2486-99; PMID:23531216; http://dx.doi.org/10.2174/0929867311320190008
   PubMed Web of Science ®Google Scholar
• Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang C-Y, Li Y, Li X, Chen C-T, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010; 18:423-35; PMID:21075308; http://dx.doi.org/10.1016/j.ccr.2010.10.025
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123:1957-60; PMID:24652965; http://dx.doi.org/10.1182/blood-2014-01-547869
   PubMed Web of Science ®Google Scholar
• Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013; 31:128-30; PMID:23045586; http://dx.doi.org/10.1200/JCO.2012.44.4281
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117:591-4; PMID:20959606; http://dx.doi.org/10.1182/blood-2010-03-275305
   PubMed Web of Science ®Google Scholar
• Maira S-M, Stauffer F, Schnell C, García-Echeverría C. PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 2009; 37:265-72; PMID:19143644; http://dx.doi.org/10.1042/BST0370265
   PubMed Web of Science ®Google Scholar
• Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010; 24:1781-4; PMID:20703254; http://dx.doi.org/10.1038/leu.2010.154
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, et al. Role of phosphatidylinositol 3’-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108:4178-86; PMID:16946303; http://dx.doi.org/10.1182/blood-2006-04-016907
   PubMed Web of Science ®Google Scholar
• Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C, Dumontet C. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011; 10:178-85; PMID:21220500; http://dx.doi.org/10.1158/1535-7163.MCT-10-0385
   PubMed Web of Science ®Google Scholar
• Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7:1851-63; PMID:18606717; http://dx.doi.org/10.1158/1535-7163.MCT-08-0017
   PubMed Web of Science ®Google Scholar
• Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Fournié J-J, Laurent G, Bezombes C. Rituximab inhibits B-cell receptor signaling. Blood 2010; 115:985-94; PMID:19965664; http://dx.doi.org/10.1182/blood-2009-08-237537
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507-16; PMID:23782157; http://dx.doi.org/10.1056/NEJMoa1306220
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369:32-42; PMID:23782158; http://dx.doi.org/10.1056/NEJMoa1215637
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371:213-23; PMID:24881631; http://dx.doi.org/10.1056/NEJMoa1400376
   PubMed Web of Science ®Google Scholar
• Hallek M, Kay NE, Osterborg A, Chanan-Khan AA, Mahler M, Salman M, Wan Y, Sun S, Zhuang SH, Howes A. The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol Lond Engl 2014; 1-9; PMID:24901734; http://dx.doi.org/10.2217/fon.14.119
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370:997-1007; PMID:24450857; http://dx.doi.org/10.1056/NEJMoa1315226
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31:88-94; PMID:23045577; http://dx.doi.org/10.1200/JCO.2012.42.7906
   PubMed Web of Science ®Google Scholar
• Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011; 13:R115; PMID:21752263; http://dx.doi.org/10.1186/ar3400
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003; 9:5866-73; PMID:14676108
   PubMed Web of Science ®Google Scholar
• Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouillé V, Quittet P, Klein B, Rossi J-F. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008; 26:2725-31; PMID:18427151; http://dx.doi.org/10.1200/JCO.2007.13.7729
   PubMed Web of Science ®Google Scholar
• Clémenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, Vié H. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood 2006; 107:4669-77; PMID:16514054; http://dx.doi.org/10.1182/blood-2005-09-3775
   PubMed Web of Science ®Google Scholar